Brought to you by 
HPA spin-off Syntaxin gets £3mm in first venture round
04 Jan 2006
Executive Summary
Abingworth Management invested £3mm ($5.2mm) in start-up biotech Syntaxin, a spin-off of the UK Health Protection Agency (HPA) that is engaged in the discovery and development of neurological, respiratory, and metabolic disease therapeutics.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
HPA spin-off Syntaxin gets £3mm in first venture round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice